Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Uncommon anal neoplasms.

Kevin G Billingsley1, Lawrence E Stern, Andrew M Lowy

  • 1Division of Surgical Oncology, Department of Surgery, Oregon Health Sciences University, 3181 S.W. Sam Jackson Park Road, Portland, OR 97239, USA.

Surgical Oncology Clinics of North America
|May 13, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient-derived organoids reveal ductal dysfunction and CFTR-modulator responses in chronic pancreatitis.

Cell stem cell·2026
Same author

HDAC inhibition sensitizes pancreatic tumors to DNA damage by global redistribution of the transcriptional machinery.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Bridging the Gap: Examining the Association of Travel Burden With Treatment Administration and Survival in Stage II/III Gastric Cancer.

JCO oncology practice·2026
Same author

CA19-9 induces microenvironment remodeling in pancreatic ductal adenocarcinoma.

bioRxiv : the preprint server for biology·2026
Same author

HDAC INHIBITION SENSITIZES PANCREATIC TUMORS TO DNA DAMAGE BY GLOBAL REDISTRIBUTION OF THE TRANSCRIPTIONAL MACHINERY.

bioRxiv : the preprint server for biology·2026
Same author

Targeting the αvβ5 Integrin Modifies the TGF-β-Rich Tumor Microenvironment of Pancreatic Cancer.

Cancer research·2026

Rare anal neoplasms lack standardized treatment guidelines. Future Phase II clinical trials could establish uniform protocols and benchmarks for improved patient care algorithms.

Area of Science:

  • Oncology
  • Surgical Pathology

Background:

  • Anal neoplasms are uncommon, leading to a lack of evidence-based diagnostic and treatment protocols.
  • Current management strategies are not consistently derived from prospective clinical trial data.

Purpose of the Study:

  • To highlight the need for developing standardized diagnostic and treatment algorithms for rare anal neoplasms.
  • To propose the design of prospective clinical trials to address current evidence gaps.

Main Methods:

  • Review of existing literature and clinical practices for anal neoplasms.
  • Proposal for the design of prospective Phase II clinical trials.

Main Results:

  • Identified a critical need for prospective clinical trials in managing anal neoplasms.

Related Experiment Videos

  • Suggested the establishment of uniform surgical pathology, surgical technique guidelines, and endpoints for future trials.

    • Conclusions:

    • Prospective clinical trials are essential for developing evidence-based algorithms for rare anal neoplasms.
    • The American College of Surgeons Oncology Group could lead the design and execution of such trials to set modern patient care benchmarks.